United States · Series A startup

Who invested in 3T Biosciences

One round we have observed, with the 3 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Pharma

Funding summaryUpdated 26 Oct 2026

$40Mraised across 1 round since 2022, from 1 source

Latest round
Series A, $40MAug 2022
Investors
3
See who backed them

The rounds

  1. Aug 2022

Founders and team

From 3T Biosciences's own website: 1 on the team.

  • Christopher J DeRespinoChief Business Officer

Everyone who backed them

Menlo VenturesVC firm1round
CRVVC firm1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

These 3 firms list 3T Biosciences as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.

Collaborative FundVC firmPer its own site
Asset Management VenturesVC firmPer its own site
Westlake Village BiopartnersAcceleratorPer its own site

Quick answers about 3T Biosciences

Who invested in 3T Biosciences?

3T Biosciences's investors include Lightspeed Venture Partners, Menlo Ventures and CRV.

How much has 3T Biosciences raised?

3T Biosciences has raised $40M across 1 round since 2022.

When did 3T Biosciences last raise?

3T Biosciences's most recent round was a Series A of $40M in Aug 2022.

What was 3T Biosciences's biggest round?

Its most recent round, $40M in Aug 2022, is also its largest on record.

Who backed 3T Biosciences first?

3T Biosciences's first round on record, in Aug 2022, was backed by Lightspeed Venture Partners, Menlo Ventures and CRV.

What stage is 3T Biosciences at?

3T Biosciences's latest named round is a Series A, in Aug 2022.

Where is 3T Biosciences based?

3T Biosciences is based in the United States.

Companies like 3T Biosciences

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.